Chlorpheniramine: Clinical Trials

21 trials of Chlorpheniramine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 4 unknown, 3 recruiting, 3 terminated. 8 Phase 2, 5 Phase 3, 4 Phase 1, 3 Not applicable, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 3, Completed 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 35Completed 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 14Completed 4
Not applicable3Completed 2, Unknown 1
Phase 42Completed 1, Recruiting 1
Early Phase 11Completed 1

Follow Chlorpheniramine: new trials by email Literature Review of Chlorpheniramine trials Research Report on Chlorpheniramine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults
dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg, dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg, Placebo - Common Cold/Flu, Nasal Congestion
Phase 3RecruitingBrainfarma Industria Química e Farmacêutica S/A6202026-05-082026-06-16
Antihistamine for Prevention of HTR After Blood Primed CPB
Antihestamine, Placebo - Blood Transfusion Associated Adverse Reactions
Phase 4RecruitingKasr El Aini Hospital402026-03-012026-04-21
First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study
Chlor-Trimeton. - Voice Disorder Due to Iatrogenic Factor
Early Phase 1CompletedAuburn University82023-06-132024-04-24
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs
Phase 2 / Phase 3CompletedDr. Ferrer BioPharma1572022-07-272023-06-02
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I
Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs
Phase 2 / Phase 3CompletedDr. Ferrer BioPharma1012021-12-072023-03-23
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray - COVID-19, COVID-19 Pandemic
UnknownDr. Ferrer BioPharma10002021-08-262022-08-30
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
Placebo, Chlorpheniramine - Allergic Transfusion Reaction
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China66422021-01-012026-11-12
Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis
CPM, Placebo - Allergic Rhinitis, Nasal Congestion
Phase 2 / Phase 3WithdrawnLarkin Community Hospital2019-07-302023-10-16
Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions
Chlorthalidone (HIGROTON® 50), Losartan (COZZAR®), A1+ A2 Co-administration of Chlorthalidone and Losartan - Healthy
Phase 1CompletedLaboratorios Silanes S.A. de C.V.362019-05-012021-10-22
Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy
Chlorpheniramine and midazolam, Midazolam - Endoscopy
Not applicableUnknownSeoul National University Hospital2202019-05-012020-04-17
Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research
electroacupuncture, antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate), antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate) - Pain
Not applicableCompletedChina Medical University Hospital402019-01-242020-01-09
Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine
Chlorpheniramine and ranitidine, 0.9% Normal Saline - Protamine Adverse Reaction
Phase 4CompletedMahidol University402018-09-052021-09-01
Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn
SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg, 2 capsules Ibuprofen and 1 placebo, capsule Chlorpheniramine 4mg and 1 Placebo - Sunburn
Phase 2TerminatedSephoris Pharmaceuticals LLC802018-01-152019-09-27
Exploratory Study for Allergy Relief Onset
Chlorpheniramine maleate (BAY X002134), Placebo - Rhinitis, Allergic
Phase 2TerminatedBayer12016-05-072018-12-12
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
ARC-520, Placebo, entecavir - Hepatitis B, Chronic
Phase 2TerminatedArrowhead Pharmaceuticals582014-03-012026-01-13
StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg - Rhinitis, Seasonal, Allergic
Phase 2UnknownMagna Pharmaceuticals, Inc.1252014-03-012014-05-30
Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Chlorphenamine and Ranitidine, Paracetamol - Poisoning
Not applicableCompletedUniversity of Edinburgh242011-01-032024-06-20
Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome
Resfenol, Placebo, Co interventional acetaminophen - Common Cold, Flu-like Syndrome
Phase 3UnknownHospital de Clinicas de Porto Alegre1462009-06-012009-07-16
Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents
Chlorpheniramine - Allergic Reactions
Phase 1CompletedWyeth is now a wholly owned subsidiary of Pfizer362008-12-212020-10-23
Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension
Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension - Healthy
Phase 1CompletedMallinckrodt432003-09-012016-10-19

Showing 20 of 21. Sign in to see all of them.

Conditions studied

COVID-19 (3)  ·  Common Cold (2)  ·  Coronavirus Infections (2)  ·  Nasal Obstruction (2)  ·  Rhinitis, Allergic (2)  ·  Signs and Symptoms (2)  ·  Anaphylaxis (1)  ·  Hepatitis (1)  ·  Hepatitis B, Chronic (1)  ·  Hypersensitivity (1)  ·  Influenza, Human (1)  ·  Pain (1)  ·  Poisoning (1)  ·  Rhinitis (1)  ·  Rhinitis, Allergic, Seasonal (1)

Sponsors

Dr. Ferrer BioPharma (3)  ·  Mallinckrodt (2)  ·  Arrowhead Pharmaceuticals (1)  ·  Auburn University (1)  ·  Bayer (1)  ·  Brainfarma Industria Química e Farmacêutica S/A (1)  ·  China Medical University Hospital (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Kasr El Aini Hospital (1)  ·  Laboratorios Silanes S.A. de C.V. (1)  ·  Larkin Community Hospital (1)  ·  Magna Pharmaceuticals, Inc. (1)  ·  Mahidol University (1)  ·  Seoul National University Hospital (1)

Countries

United States (5)  ·  Brazil (2)  ·  Honduras (2)  ·  China (1)  ·  Dominican Republic (1)  ·  Egypt (1)  ·  Hong Kong (1)  ·  Mauritius (1)  ·  Mexico (1)  ·  South Korea (1)  ·  Taiwan (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Herbert Neuman, MD (2)  ·  Araceli G Medina Nolasco, M.D (1)  ·  Bruce Given, MD (1)  ·  Euan A Sandilands, MRCP BSc (1)  ·  Gitanjali Petkar, M.D (1)  ·  Liz J Medina Reyes, M.D (1)  ·  Marcos A Sanchez-Gonzalez (1)  ·  Mary J Sandage, PhD (1)  ·  Sirilak Suksompong, MD (1)  ·  Stephen J Pollard, MD (1)  ·  Yi-Hung Chen, PhD (1)

Results publications

PMID 16377322, PMID 24893689, PMID 28159539, PMID 29136286, PMID 29689257, PMID 33712437, PMID 36081814, PMID 36571171